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Abstract
Background: IFN-γ responses to M. tuberculosis antigens are used as in-vitro diagnostic tests for
tuberculosis infection. The tests are highly specific but sensitivity may be impaired due to immuno-
suppression. The objective of this small exploratory study was to compare three novel biomarkers
for in-vitro diagnosis of tuberculosis – MCP-1, MCP-3 and IL-1RA – with the current established
biomarker IFN-γ and the newly described IP-10 and MCP-2.
Methods: Whole blood from 8 patents with active tuberculosis and from 7 healthy controls was
stimulated with M. tuberculosis specific antigens and mitogen in the Quantiferon In Tube test tubes.
Levels of biomarkers were measured using Luminex and ELISA (IFN-γ).
Results: We found all five new biomarkers were expressed in significantly higher concentrations
compared to IFN-γ. IP-10 and MCP-3 levels in the un-stimulated samples were higher in patients
compared with controls.
Conclusion: All biomarkers had diagnostic potential as they could differentiate between the
patients and the controls. IP-10 and MCP-2 seemed most promising as they were expressed in high
levels with antigen stimulation and were low in the un-stimulated samples. Further studies are
needed to explore the potential of these highly expressed novel biomarkers individually and in
combination.
Background
Until recently the tuberculin skin test has been the key
tool in the diagnosis of latent tuberculosis infection, but
with the identification of three Mycobaterium tuberculosis
(TB) specific protein antigens (ESAT-6, CFP10, and TB
7.7) a new generation of diagnostic tests has emerged.
These tests measure interferon gamma (IFN-γ) release
after the stimulation of whole blood or blood compo-
nents with the antigens and are known as Interferon
Gamma Release Assays (IGRA). The tests have proved to
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be both sensitive and specific for the detection of TB infec-
tion[1]. However, new reports suggest that the sensitivity
of the IGRA may not be as high as expected in patients
with active TB, and that patients with advanced HIV and
severe immuno-suppression have an increased propor-
tion of indeterminate results ([1-7] Aabye et al in prep).
Alternative biomarkers expressed in higher amounts
could prove less susceptible to immuno-suppression and
could therefore be used in future developments of the
IGRA tests. In this short communication we have com-
pared the diagnostic potential of three novel biomarkers –
CCL2/MCP-1, CCL7/MCP-3 and IL-1RA – with the cur-
rent established biomarker IFN-γ and the newly described
CXCL10/IP-10 and CCL8/MCP-2.
CXCL10 or Interferon induced protein (IP)-10 is a CXC
chemokine mainly produced by monocytes and T cells.
IP-10 is elevated in the serum of TB patients[8], and we
have recently shown that IP-10 is produced in a highly
antigen-dependent manner following M. tuberculosis anti-
gen challenge[9]. We have shown that a diagnostic test for
infection with M. tuberculosis using IP-10 performed com-
parably with a commercial IGRA in both active and latent
TB disease ([10,11], Aabye et al in prep). CCL8 or mono-
cyte chemoattractant protein (MCP)-2 is a CC chemokine
that mainly attracts monocytes and T cells [12] and MCP-
2 mRNA is upregulated in monocytes following infection
by M. tuberculosis[13]. Similar to IP-10 we have recently
demonstrated that MCP-2 expression is induced upon
antigen challenge in the IGRA test assay, and that it holds
diagnostic potential[11]. Interleukin 1 receptor antago-
nist (IL-1RA) is a natural antagonist of IL-1 produced by
macrophages. IL-1RA has been suggested as a marker for
TB disease activity and response to treatment[14]. CCL2
or MCP-1 is a CC chemokine which primarily targets
monocytes and T cells[12,15]. MCP-1 is produced by PPD
challenge in vitro [16] and serum levels have been associ-
ated with TB disease activity and treatment response([17],
Heeland M, et al in prep). CCL7 or MCP-3 is produced by
macrophages and attracts monocytes [12]. MCP-3 has
been found elevated in bronchoalveolar lavage fluid and
biopsy specimens of subjects with pulmonary tuberculo-
sis[18].
Methods
Patient material
This study included eight patients with active tuberculosis
and seven healthy unexposed controls. Four of the
patients were from the study area of the Bandim Health
Project in Guinea Bissau, West Africa of which all were
diagnosed TB positive using sputum smear microscopy
and/or clinical evaluation according to WHO guidelines.
The remaining four TB patients were included from the
department of infectious diseases at the Copenhagen Uni-
versity, Hvidovre Hospital all of which were sputum-
smear-positive and culture positive. The seven healthy
controls were recruited among junior doctors and stu-
dents at Copenhagen University, Hvidovre Hospital. The
median age of the TB patients was 44 (range 20–71) and
32 (28–34) for the controls. All TB patients were tested
HIV negative; and all were included within the first two
weeks of chemotherapy, median 0 days (range 0–14
days).
The study was approved by the Ethical Committee of
Copenhagen and Frederiksberg Commune
(KF01278477) and the Ethical Committee of Guinea Bis-
sau.
Whole blood stimulation
Briefly, 1 ml of blood was drawn directly into vaccutainer
tubes from Cellestis (Carnegie, Australia). The tubes were
precoated with saline (un-stimulated negative control),
peptides of ESAT-6, CFP10 and TB 7.7 (the M. tuberculosis
specific antigens), or PHA (positive mitogen control). The
tubes were incubated for 20–24 hours at 37°C, and
plasma was harvested and frozen until further analysis.
Biomarker determination
The amount of IFN-γ produced was determined by ELISA
using the manufacturer's instructions http://www.celles
tis.com/ and IFN-γ measurements were shown in pg/ml to
facilitate the comparison with other biomarkers as
described previously[9]. One International Unit (IU) of
IFN-γ corresponds to 50 pg (NIBSC, Hertfordshire, UK).
IP-10, MCP-1, MCP-2, MCP-3, and IL-1RA concentrations
were measured by xMAP technology on the Luminex plat-
form (Luminex Corporation), using Biosource reagents
(Biosource, Camarillo, USA) acquired and analyzed with
the StarStation v2.0 software (Applied Cytometry Sys-
tems) as described previously[9]. All measurements were
performed in duplicates and blinded. In preliminary stud-
ies we had observed that the antigen and mitogen induced
biomarker concentrations were above the upper limits of
quantification (data not shown), thus measurements were
performed at 1:8 dilution in assay diluent (Biosource) and
concentrations were later multiplied with the dilution fac-
tor as recommended by the manufacturer (Biosource).
Statistics
Concentration of IP-10, MCP-2, MCP-3, MCP-2, IL-1RA
and IFN-γ were compared using Kruskal-Wallis test and
Wilcoxon signed rank test. Data was analysed using SAS
9.1.3 (SAS institute, Cary, USA).
Results
Biomarker measurements
By screening 30 potential biomarkers (cytokines, chemok-
ines, soluble receptors and receptor antagosnists) we
found that IP-10, MCP-2, MCP-1, MCP-3 and IL-1RA wereBMC Research Notes 2009, 2:19 http://www.biomedcentral.com/1756-0500/2/19
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biomarkers expressed in high amounts upon challenge
with M. tuberculosis antigens compared to un-stimulated
levels (data not shown). Median and inter quartile range
of biomarkers levels in un-stimulated, antigen-, and
mitogen-stimulated whole blood from eight TB patients
and seven controls are shown in table 1. All TB patients
responded positive and all controls responded negative in
the QFT-IT test.
Table 1: Plasma IP-10, MCP-3, MCP-2, IFN-γ, MCP-1 and IL-1RA release in antigen stimulated whole blood culture
Controls (n = 7) TB patients (n = 8) p-value
IP-10
Nil 5 (5–57)1 157 (102–301) 0.0047
Antigen 46 (0–63) 9010 (5542–13785) 0.0011
Mitogen 3601 (1702–5918) 4835 (2112–7075) 0.7285
MCP-3
Nil 737 (320–1202) 3464 (1442–5517) 0.0372
Antigen 807 (147–1236) 9206 (7221–11296) 0.0012
Mitogen 2224 (1724–2964) 9393 (4538–13966) 0.0109
MCP-2
Nil 24 (17–43) 26 (24–46) 0.4724
Antigen 33 (24–43) 2208 (914–3781) 0.0012
Mitogen 4673 (1908–6601) 3379 (474–5592) 0.4875
IFN-γ
Nil 8 (7–9) 8 (7–14) 0.4859
Antigen 8 (6–9) 223 (179–601) 0.0012
Mitogen 1326 (534–1363) 327 (92–724) 0.0279
MCP-1
Nil 6352 (3110–13560) 6120 (4723–15527) 0.8170
Antigen 7206 (5368–12471) 44991 (25831–56822) 0.0012
Mitogen 27773 (20500–42559) 46926 (26396–80328) 0.2030
IL-1RA
Nil 3371 (1277–7983) 6328 (3035–9415) 0.4875
Antigen 3986 (2386–6893) 26002 (18226–33934) 0.0054
Mitogen 54397 (29233–77086) 15966 (12106–27296) 0.0091
1 Median (Inter Quartile Range)BMC Research Notes 2009, 2:19 http://www.biomedcentral.com/1756-0500/2/19
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In whole blood cultures from all TB patients the antigens
induced significant elevations in the levels of all 6 biomar-
kers compared to the controls (p < 0.006). The un-stimu-
lated IP-10, MCP-2 and IFN-γ levels were significantly
lower compared to MCP-1 (p < 0.0001), MCP-3 (p <
0.0001), and IL-1RA (p < 0.0001). But, un-stimulated IP-
10 and MCP-3 levels among TB patients were significantly
higher compared to controls (p < 0.04). Mitogen stimula-
tion resulted in an increase in all biomarkers in both con-
trol and patient samples (p < 0.0001).
Antigen-dependent biomarker production
The antigen-dependent biomarker expression was evalu-
ated by subtracting the concentration in the un-stimulated
tube from the levels measured in the antigen-stimulated
tube. The individual measurements are depicted in figure
1a–b. The antigen-dependent biomarker levels were sig-
nificantly higher in TB patients compared to controls (p <
0.006). For the TB patients the median antigen-dependent
levels were: 31,962 pg/ml (range 10,354–49,276 pg/ml)
for MCP-1, 18,254 pg/ml (1,297–35,458 pg/ml) for IL1-
RA, 8,778 pg/ml (1,800–24,355 pg/ml) for IP-10, 5,918
pg/ml (1,812–13,658 pg/ml) for MCP-3 and 1,990 pg/ml
(444–5,523 pg/ml) for MCP-2, and 215 pg/ml (64–1,018
pg/ml for INF-γ. The antigen-dependent IP-10, MCP-2,
and IFN-γ concentrations in the controls were consistently
low whereas one control responded with some antigen-
dependent MCP-1, MCP-3 and IL-1RA production,
another with some MCP-3 and IL-1RA production, and a
third responded with some MCP-3 production (figure 1).
IP-10, MCP-2, MCP-3, MCP-2 and IFN-γ, but not IL-1RA
differentiated completely between patients and controls.
Discussion
The ideal diagnostic biomarker gives a binary signal that
clearly differentiates between healthy and infected indi-
viduals, and between different stages of disease e.g. latent
and active disease. In the less perfect world of cellular
assays for TB diagnosis, a good biomarker has low levels
in un-stimulated samples, no response to antigen in sam-
ples from uninfected individuals, and strong responses to
antigen in samples from patients. Till this date no biomar-
ker can differentiate between active and latent TB. The two
commercially available IGRA tests use IFN-γ as biomarker
for TB infection. IFN-γ fulfils the criteria of low levels in
un-stimulated samples and no responses to antigen in
uninfected, but the levels expressed in response to anti-
gens are low. To achieve maximum sensitivity, the cut off
point for a positive IFN-γ test is set at the lowest possible
level[19]. A recent meta-analysis estimated overall test
sensitivity to be 70% – 90% and specificity 93 – 99%
(depending on assay), and test performance is compro-
mised in immuno-compromised individuals ([1,5],
Aabye et al in prep)
This small proof of principle study compares three novel
biomarkers for in-vitro diagnosis of TB with the current
established biomarker IFN-γ and the newly identified IP-
10 and MCP-2. The main new findings are that MCP-1,
MCP-3, and IL-1RA all were induced in-vitro in response
to antigen stimulation in significantly higher amounts in
patients than in controls. All biomarkers were specifically
induced after antigen-stimulation of whole blood from
patients but not from controls, indicating a diagnostic
potential. IP-10, MCP-3, and especially MCP-1, and IL-
1RA were expressed in very high antigen-dependent levels
in patients, but one patient had a low IL-1RA response.
Some of the unexposed controls responded with antigen-
dependent MCP-1, MCP-3, and IL-1RA production to the
antigens, indicating that these biomarkers could be less
specific. As seen in other studies the IP-10 levels were
induced in higher levels upon antigen compared to
mitogen stimulation[10,11]. This probably reflect that the
PHA mitogen targets T cells and induce an IFN signal that
downstream induces an IP-10 signal from the monocytes
present in the sample. In contrast the antigen-dependent
IP-10 signal is a result of a convergence of signals both
from cell surface receptor interaction between the T cell
and the Monocyte, and cytokine stimulation. Un-stimu-
lated levels of IP-10 and MCP-3 were significantly higher
in TB patients both from Denmark and from Guinea-Bis-
sau compared with the levels seen in controls (table 1).
We and others have observed this phenomenon for IP-
10[8,9], but it has not been observed before for MCP-3.
The levels of IP-10 present in the blood plasma at time of
phlebotomy correlate to the levels of IP-10 seen in the un-
stimulated sample (unpublished observation) and high
levels appear to reflect severe infection[8]. Whether differ-
ences in un-stimulated levels of IP-10 and MCP-3 can be
used in conjunction with antigen specific responses to dif-
ferentiate active from latent TB disease, remains to be
explored.
Conclusion
In conclusion we have identified three novel potential in-
vitro biomarkers for tuberculosis infection MCP-1, MCP-3
and IL-1RA. Of the biomarkers studied, MCP-2 and IP-10
held the most promise as the un-stimulated levels were
low, and the antigen-simulated levels were high in
patients and not in controls. Both biomarkers were
expressed in much higher concentration compared to
IFN-γ. Although the results of IP-10 and MCP-2 reproduce
findings from more well powered studies the sample size
is small and there is a risk of type 1 error. Further studies
are needed to explore the potential of these novel biomar-
kers individually and in combination.
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Whole blood of eight patients with active TB, and seven healthy unexposed controls was stimulated 20 hours with either saline  or M. tuberculosis specific antigens Figure 1
Whole blood of eight patients with active TB, and seven healthy unexposed controls was stimulated 20 hours 
with either saline or M. tuberculosis specific antigens. Biomarker production was measured in plasma supernatant by 
ELISA (IFN-γ) and multiplex technology (IP-10, MCP-3, MCP-2, IL-1RA and MCP-1). Antigen-dependent production represent 
the antigen stimulated sample subtracted the un-stimulated sample. Straight lines represent median values. Differences 
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